Form 4 for BSX Boston Scientific
Accepted 2022-02-17 00:00:00 ET · period of report 2022-02-15 · accession 0001225208-22-002658 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-17 | 2022-02-15 | BSX | Brennan Daniel J. | EVP, CFO | F - Tax | $44.01 | -1,219 | 275.3K | -0.4% | -$53.6K |
| DM | 2022-02-17 | 2022-02-15+ | BSX | Brennan Daniel J. | EVP, CFO | M - OptEx | $4.68 | +16.3K | 278.4K | +6% | +$76.5K |
| DM | 2022-02-17 | 2022-02-15+ | BSX | Brennan Daniel J. | EVP, CFO | S - Sale+OE | $43.60 | -21.3K | 266.2K | -7% | -$929.7K |
| DM | 2022-02-17 | 2022-02-16 | BSX | Brennan Daniel J. | EVP, CFO | A - Grant | $0.00 | +65.5K | 17.0K | New | $0 |
| DM | 2022-02-17 | 2022-02-15+ | BSX | Brennan Daniel J. | EVP, CFO | M - OptEx | $0.00 | -16.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-15 | F | D | 1,219 | $44.01 | 275,313 | D | — | — | |
| 2 | Common | Common Stock | 2022-02-15 | M | A | 4,153 | $0.00 | 276,532 | D | — | — | (F1) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| 3 | Common | Common Stock | 2022-02-16 | S | D | 12,187 | $43.70 | 266,177 | D | — | — | (F4) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.84, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2022-02-16 | M | A | 12,187 | $6.28 | 278,364 | D | — | — | |
| 5 | Common | Common Stock | 2022-02-15 | S | D | 9,136 | $43.47 | 266,177 | D | — | — | (F3) Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.32 to $43.62, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-02-16 | A | A | 48,529 | $0.00 | 48,529 | D | $44.19 · — to 2032-02-16 | 48,529 Common Stock | (F8) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
| 7 | Derivative | Restricted Stock Units | 2022-02-16 | A | A | 16,972 | $0.00 | 16,972 | D | — · — to 2026-02-16 | 16,972 Common Stock | (F6) Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F7) Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
| 8 | Derivative | Deferred Stock Units | 2022-02-15 | M | D | 4,153 | $0.00 | 4,153 | D | — · — to 2023-02-15 | 4,153 Common Stock | (F1) Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. (F5) Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |
| 9 | Derivative | Stock Option (Right to Buy) | 2022-02-16 | M | D | 12,187 | $0.00 | 0 | D | $6.28 · — to 2022-02-27 | 12,187 Common Stock | (F9) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. |